Join
Live feed
·
PRReleasevia Quantisnow
Praxis Precision Medicines Inc. logo

Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3

ByQuantisnow·Wall Street's wire, on your screen.
PRAX· Praxis Precision Medicines Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PRAX (Praxis Precision Medicines Inc.) and more on Quantisnow.